Literature DB >> 24345710

Understanding depot antipsychotics: an illustrated guide to kinetics.

Jonathan M Meyer1.   

Abstract

Long-acting injectable (LAI) antipsychotics can have considerable advantages over oral medications for the management of patients with schizophrenia. Despite the high prevalence of treatment nonadherence with oral pharmacotherapy, LAI antipsychotics are significantly underutilized in this patient population. The availability of newer LAI antipsychotic preparations combined with a resurgent interest in the use of typical antipsychotics has rekindled awareness of the value of LAI medications. This article is intended to provide a visual understanding of the various kinetic profiles of LAI antipsychotics to facilitate initiation and greater use of these agents.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24345710     DOI: 10.1017/S1092852913000783

Source DB:  PubMed          Journal:  CNS Spectr        ISSN: 1092-8529            Impact factor:   3.790


  8 in total

1.  Comparative effectiveness of long-acting antipsychotics: issues and challenges from a pragmatic randomised study.

Authors:  G Ostuzzi; C Barbui
Journal:  Epidemiol Psychiatr Sci       Date:  2015-10-30       Impact factor: 6.892

2.  Efficacy of Transcranial Direct-Current Stimulation in Catatonia: A Review and Case Series.

Authors:  Alexandre Haroche; Nolwenn Giraud; Fabien Vinckier; Ali Amad; Jonathan Rogers; Mylène Moyal; Laetitia Canivet; Lucie Berkovitch; Raphaël Gaillard; David Attali; Marion Plaze
Journal:  Front Psychiatry       Date:  2022-04-27       Impact factor: 5.435

Review 3.  Newer Formulations of Risperidone: Role in the Management of Psychotic Disorders.

Authors:  Ivana Clark; David Taylor
Journal:  CNS Drugs       Date:  2020-08       Impact factor: 5.749

4.  Medication adherence in patients with psychotic disorders: an observational survey involving patients before they switch to long-acting injectable risperidone.

Authors:  Franck Jean Baylé; Arnaud Tessier; Sophie Bouju; David Misdrahi
Journal:  Patient Prefer Adherence       Date:  2015-09-16       Impact factor: 2.711

Review 5.  Clinical benefits and impact of early use of long-acting injectable antipsychotics for schizophrenia.

Authors:  Georgia L Stevens; Gail Dawson; Jacqueline Zummo
Journal:  Early Interv Psychiatry       Date:  2015-09-25       Impact factor: 2.732

6.  Haloperidol inactivates AMPK and reduces tau phosphorylation in a tau mouse model of Alzheimer's disease.

Authors:  Jeremy Koppel; Heidy Jimenez; Leslie Adrien; Blaine S Greenwald; Philippe Marambaud; Ezra Cinamon; Peter Davies
Journal:  Alzheimers Dement (N Y)       Date:  2016-06-21

Review 7.  Guidance on the clinical understanding and use of long-acting injectable antipsychotics in Schizophrenia: Hong Kong Consensus Statements.

Authors:  Michael Ming Cheuk Wong; Albert Kar Kin Chung; Timothy Ming Hong Yeung; David Tai Wai Wong; Che Kin Lee; Eric Lai; Gloria Fong Yeung Chan; Gregory Kai Lok Mak; Jessica Oi Yin Wong; Roger Man Kin Ng; Ki Yan Mak
Journal:  CNS Neurosci Ther       Date:  2021-03       Impact factor: 5.243

Review 8.  Spotlight on once-monthly long-acting injectable aripiprazole and its potential as maintenance treatment for bipolar I disorder in adult patients.

Authors:  Vanessa Torres-Llenza; Pooja Lakshmin; Daniel Z Lieberman
Journal:  Neuropsychiatr Dis Treat       Date:  2018-01-11       Impact factor: 2.570

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.